Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Keros Therapeutics (KROS) EBT: 2019-2025

Historic EBT for Keros Therapeutics (KROS) over the last 7 years, with Sep 2025 value amounting to -$8.7 million.

  • Keros Therapeutics' EBT rose 83.56% to -$8.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $71.1 million, marking a year-over-year increase of 137.89%. This contributed to the annual value of -$187.1 million for FY2024, which is 22.26% down from last year.
  • Latest data reveals that Keros Therapeutics reported EBT of -$8.7 million as of Q3 2025, which was up 73.56% from -$32.9 million recorded in Q2 2025.
  • In the past 5 years, Keros Therapeutics' EBT registered a high of $158.5 million during Q1 2025, and its lowest value of -$53.0 million during Q3 2024.
  • For the 3-year period, Keros Therapeutics' EBT averaged around -$21.8 million, with its median value being -$43.1 million (2024).
  • Its EBT has fluctuated over the past 5 years, first crashed by 501.46% in 2022, then surged by 467.62% in 2025.
  • Quarterly analysis of 5 years shows Keros Therapeutics' EBT stood at -$4.9 million in 2021, then slumped by 501.46% to -$29.7 million in 2022, then tumbled by 56.32% to -$46.5 million in 2023, then rose by 1.57% to -$45.7 million in 2024, then skyrocketed by 83.56% to -$8.7 million in 2025.
  • Its last three reported values are -$8.7 million in Q3 2025, -$32.9 million for Q2 2025, and $158.5 million during Q1 2025.